Naslov
Serumska endotelna lipaza, lipidni i upalni pokazatelji u bolesnika s akutnim zatajivanjem srca i metaboličkim sindromom
(Serum level of endothelial lipase, lipid and inflammatory biomarkers in patients with acute heart failure and overlapping metabolic syndrome)

Autori
Potočnjak, Ines

Vrsta, podvrsta i kategorija rada
Ocjenski radovi, doktorska disertacija

Fakultet
Medicinski fakultet

Mjesto
Zagreb

Datum
22.12

Godina
2016

Stranica
95

Mentor
Degoricija, Vesna

Ključne riječi
zatajivanje srca ; metabolički sindrom ; endotelna lipaza ; lipidi ; upalni pokazatelji
(heart failure ; metabolic syndrome ; lipase ; lipids ; markers.)

Sažetak
PhD candidate: Ines Potočnjak, MD Affiliation/s: University of Zagreb School of Medicine, Sisters of Charity University Hospital Center, Zagreb, Croatia Part of the thesis: Elevated serum level of endothelial lipase, inflammatory markers and lipid profile in metabolic syndrome are significant prognostic factors in development of acute heart failure. Mentor/s: Professor Vesna Degoricija, MD, PhD Introduction: Heart failure (HF) is defined as an abnormality of cardiac structure or function lesion leading to failure of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues, despite normal filling pressures. Metabolic syndrome (MS) is a tendency of concomitant risk factors to group: central obesity, elevated serum triglycerides, lowered HDL-cholesterol, glucose intolerance and hypertension. Since MS is present in 35% of patients with acute HF (AHF), this overlapping is important for further investigation. Hypothesis: Elevated serum level of endothelial lipase, inflammatory markers and lipid profile in AHF patients with overlapping MS produce worse outcome. Aims: To investigate whether elevated serum level of endothelial lipase, inflammatory markers and lipid profile can predict worse outcome in patients with AHF and overlapping MS. Material and methods: The study will be observational, prospective and performed on AHF patients recruited from the Sisters of Charity University Hospital Center, Zagreb, Croatia, in a roughly estimated period of 12 months. Patients will be divided in two groups depending on the presence of MS. The groups will be compared by analysing lipid profile and inflammatory biomarkers considering the following parameters: total lipids, cholesterol, HDL, LDL, triglycerides, VLDL, endothelial lipase (EL), EL gene genotyping aimed at detecting known polymorphisms responsible for EL enzyme activity, lipoprotein A, hs-CRP, IL6, IL8, HDL subtypes, paraoxonase activity in HDL, and its total anti- inflammatory activity. Patients will be treated according to standard treatment protocol. The study will be performed according to Good Clinical Practice and Helsinki Declaration’s principles, and approved by the local Ethics Committee. Input parameters will include the patients’ data: medical history, current clinical status, laboratory and diagnostic procedures. Additionally, 3x6mL of full blood samples will be collected, two at admission, and one on the third day of hospitalisation, immediately centrifuged, with serum divided into plastic tubes, and frozen at -30°C. Once sample collection is completed, serum biochemical analysis will be performed at the Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University Graz, Austria. Output parameters will include outcome measures: treatment duration, performed procedures, mortality and NYHA classification. Expected scientific contribution: The results should determine that investigated increased laboratory markers can be predictors of morbidity and mortality of AHF patients with overlapping MS. Acknowledgments: I would like to thank team members for collaboration on this project: Vesna Degoricija1, 2, Saša Frank3, Sanda Dokoza Terešak1, and Bojana Radulović4 ; 1Sisters of Charity University Hospital Center, Zagreb, Croatia, 2University of Zagreb, School of Medicine, Zagreb, Croatia, 3Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University Graz, Austria, 4Clinical Hospital Center Zagreb, Zagreb, Croatia. A special appreciation for informatics support goes to Dubravko Rutalj. I would like to emphasise special gratitude for collaboration with Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University Graz, Austria (Austrian Science Foundation (FWF ; grant) 2013-2016).

Izvorni jezik
Hrvatski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA